###begin article-title 0
Persisting Mixed Cryoglobulinemia in Chikungunya Infection
###end article-title 0
###begin p 1
Conceived and designed the experiments: MO FS. Performed the experiments: MO EBN HT FS. Analyzed the data: CM CR. Contributed reagents/materials/analysis tools: MO MG HT JLM PK MM JJM PJ. Wrote the paper: MO HT PP FS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 17 <span type="species:ncbi:37124">Chikungunya virus</span>
Chikungunya virus (CHIKV), an arbovirus, is responsible for a two-stage disabling disease, consisting of an acute febrile polyarthritis for the first 10 days, frequently followed by chronic rheumatisms, sometimes lasting for years. Up to now, the pathophysiology of the chronic stage has been elusive. Considering the existence of occasional peripheral vascular disorders and some unexpected seronegativity during the chronic stage of the disease, we hypothesized the role of cryoglobulins.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
From April 2005 to May 2007, all travelers with suspected CHIKV infection were prospectively recorded in our hospital department. Demographic, clinical and laboratory findings (anti-CHIKV IgM and IgG, cryoglobulin) were registered at the first consultation or hospitalization and during follow-up.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 375 383 <span type="species:ncbi:9606">patients</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
###xml 694 702 <span type="species:ncbi:9606">patients</span>
Among the 66 travelers with clinical suspicion of CHIKV infection, 51 presented anti-CHIKV IgM. There were 45 positive with the serological assay tested at room temperature, and six more, which first tested negative when sera were kept at 4degreesC until analysis, became positive after a 2-hour incubation of the sera at 37degreesC. Forty-eight of the 51 CHIKV-seropositive patients were screened for cryoglobulinemia; 94% were positive at least once during their follow-up. Over 90% of the CHIKV-infected patients had concomitant arthralgias and cryoglobulinemia. Cryoglobulin prevalence and level drop with time as patients recover, spontaneously or after short-term corticotherapy. In some patients cryoglobulins remained positive after 1 year.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Prevalence of mixed cryoglobulinemia was high in CHIKV-infected travelers with long-lasting symptoms. No significant association between cryoglobulinemia and clinical manifestations could be evidenced. The exact prognostic value of cryoglobulin levels has yet to be determined. Responsibility of cryoglobulinemia was suspected in unexpected false negativity of serological assays at room temperature, leading us to recommend performing serology on pre-warmed sera.
###end p 9
###begin title 10
Author Summary
###end title 10
###begin p 11
###xml 0 17 <span type="species:ncbi:37124">Chikungunya virus</span>
###xml 209 217 <span type="species:ncbi:9606">patients</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
###xml 777 788 <span type="species:ncbi:11103">hepatitis C</span>
###xml 991 999 <span type="species:ncbi:9606">patients</span>
###xml 1097 1105 <span type="species:ncbi:9606">patients</span>
###xml 1259 1267 <span type="species:ncbi:9606">patients</span>
Chikungunya virus is present in tropical Africa and Asia and is transmitted by mosquito bites. The disease is characterized by fever, headache, severe joint pain and transient skin rash for about a week. Most patients experience persisting joint pain and/or stiffness for months to years. In routine practice, diagnosis is based upon serology. Since 2004 there has been an ongoing giant outbreak of Chikungunya fever in East Africa, the Indian Ocean Islands, India and East Asia. In parallel, more than 1,000 travelers were diagnosed with imported Chikungunya infection in most developed countries. Considering the clinical features of our patients (joint pain), we hypothesized that cryoglobulins could be involved in the pathophysiology of the disease as observed in chronic hepatitis C infection. Cryoglobulins, which are immunoglobulins that precipitate when temperature is below 37degreesC, can induce rheumatic and vascular disorders. From April 2005 through May 2007, we screened all patients with possible imported Chikungunya infection for cryoglobulins. They were present in over 90% of patients, and possibly responsible for the unexpected false negativity of serological assays. Cryoglobulin frequency and levels decreased with time in recovering patients.
###end p 11
###begin title 12
Introduction
###end title 12
###begin p 13
###xml 227 230 227 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Simon1">[1]</xref>
###xml 231 234 231 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Brighton1">[4]</xref>
###xml 300 303 300 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Ross1">[2]</xref>
###xml 328 331 328 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Mackenzie1">[5]</xref>
###xml 414 417 414 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Pastorino1">[6]</xref>
###xml 531 534 531 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Charrel1">[7]</xref>
###xml 662 664 662 664 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">st</sup>
###xml 726 729 726 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Josseran1">[8]</xref>
###xml 811 814 811 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Mavalankar1">[9]</xref>
###xml 864 868 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Arankalle1">[10]</xref>
###xml 1013 1016 1013 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Simon1">[1]</xref>
###xml 1017 1021 1017 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-1">[11]</xref>
###xml 1022 1026 1022 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Hochedez1">[12]</xref>
###xml 1039 1043 1039 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-2">[13]</xref>
###xml 1044 1048 1044 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-3">[14]</xref>
###xml 1230 1233 1230 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Charrel1">[7]</xref>
###xml 1234 1238 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Parola1">[15]</xref>
###xml 1320 1324 1320 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Watson1">[16]</xref>
###xml 236 253 <span type="species:ncbi:37124">Chikungunya virus</span>
###xml 1092 1100 <span type="species:ncbi:9606">patients</span>
Chikungunya fever is an emerging arboviral disease characterized by a brief fever, headache and myalgias, occasional evanescent rash, inflammatory polyarthralgias, arthritides or tenosynovitis that can last for months to years [1]-[4]. Chikungunya virus (CHIKV) was identified in the 1950s in Africa [2], and soon after in Asia [5]. It can be responsible for major epidemics, sometimes separated by silent periods [6]. From 2004 to 2006, a giant CHIKV outbreak successively swept out Kenya and most islands of western Indian Ocean [7]. In Reunion Island, the outbreak was explosive at the beginning of 2006 with a pick of 45,000 cases per week. Up to 2006 June 1st , about one third of the 770,000 residents had been infected [8]. Another huge outbreak recently stroke India with 2 to 7 million estimated cases [9], and is currently spreading to Southeastern Asia [10]. During this period, Chikungunya fever was also identified in more than 1,000 travelers returning from the epidemic areas to European countries [1],[11],[12] and the USA [13],[14]. CHIKV-infected travelers included viremic patients who returned home to countries where competent vectors are present, raising serious concern for the globalization of the disease [7],[15]. The Italian outbreak in August 2007 has demonstrated the reality of this threat [16].
###end p 13
###begin p 14
###xml 74 77 74 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Fourie1">[3]</xref>
###xml 78 81 78 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Brighton1">[4]</xref>
###xml 148 151 148 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Charrel1">[7]</xref>
###xml 152 156 152 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Borgherini1">[17]</xref>
###xml 384 388 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Borgherini1">[17]</xref>
###xml 389 393 389 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Simon2">[18]</xref>
###xml 419 422 419 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Josseran1">[8]</xref>
###xml 550 553 550 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Simon1">[1]</xref>
###xml 933 937 933 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Tedeschi1">[19]</xref>
###xml 938 942 938 942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Dispenzieri1">[20]</xref>
###xml 296 302 <span type="species:ncbi:9606">infant</span>
###xml 718 729 <span type="species:ncbi:11103">hepatitis C</span>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
During the recent CHIKV outbreaks, previously described clinical features [3],[4] as well as the low rate of asymptomatic infections were confirmed [7],[17]. The disease was also responsible for unusual and unfrequent complications, including severe newborn infections after peripartum mother-to-infant transmission, meningo-encephalitis, hepatitis, myocarditis, severe epidermolysis [17],[18] and lead to surmortality [8]. Transitory peripheral vascular disorders (PVD), mostly Raynaud syndrome, were also observed few weeks after the disease onset [1]. Considering persistent arthralgias and occasional PVD, we hypothesized that cryoglobulin could be involved in the pathophysiology of the disease, as described for hepatitis C infection. In this infection high level of mixed cryoglobulinemia is commonly detected in patients with chronic viral replication and is strongly associated with liver damage and peripheral neuropathies [19],[20].
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 16
###begin p 17
###xml 1130 1133 1130 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Simon1">[1]</xref>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 595 603 <span type="species:ncbi:9606">patients</span>
###xml 677 685 <span type="species:ncbi:9606">patients</span>
###xml 842 849 <span type="species:ncbi:9606">patient</span>
From April 2005 throughout May 2007, all patients with possible imported CHIKV infection (recent travel in Indian Ocean islands and presence or history of fever and/or arthralgias) were prospectively recorded at Laveran Military Hospital in Marseille, France. The criteria for confirmed cases were i) presence of specific anti-CHIKV IgM and/or positive RT-PCR and/or isolation of CHIKV from blood and/or specific anti-CHIKV IgG, ii) recent clinical feature consistent with CHIKV infection, iii) no other etiology identified. Demographic, clinical and laboratory findings were registered for all patients at their first consultation or hospitalization and during follow-up. For patients seen more than 10 days after the onset of illness, early clinical features were identified using a retrospective questionnaire. The clinical status of each patient was actively monitored by the same physician (FS) during consultations and/or by phone calls every 2-3 months. The early stage is defined as the first 10 days of clinical disease while second stage is defined as symptoms and signs persisting more than 10 days after disease onset [1].
###end p 17
###begin p 18
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
The same physician (FS) orally informed all patients about the requirement of blood samples to diagnose the aetiology of their polyarthralgia. The script for obtaining oral consent was accepted by the Institutional Review Board at Laveran Hospital. All patients gave their oral consent, which was noted in their individual medical file. A single blood sample of less than 50 cc was taken after consultation, when clinically required; no supplementary blood samples were taken for research.
###end p 18
###begin title 19
Laboratory Procedures
###end title 19
###begin p 20
###xml 141 144 141 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Pastorino1">[6]</xref>
###xml 435 439 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Pastorino2">[21]</xref>
###xml 928 932 898 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Oliver1">[22]</xref>
###xml 1220 1224 1190 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Musset1">[23]</xref>
###xml 1225 1229 1195 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Brouet1">[24]</xref>
###xml 1315 1319 1285 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Oliver1">[22]</xref>
###xml 1426 1430 1396 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Oliver1">[22]</xref>
###xml 1512 1516 1482 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Pastorino2">[21]</xref>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
At each consultation, patients were tested for CHIKV serology using in-house IgM-capture and IgG-sandwich enzyme-linked immunosorbent assays [6]. Serologies were performed first on sera kept at 4degreesC before analysis and second, on sera kept at 37degreesC until analysis. IgG and IgM for West Nile, dengue and Rift Valley fever viruses were also assayed. On acute sera, RT-PCR and isolation of CHIKV in Vero-E6 cells were attempted [21]. Cryoglobulinemia was screened using the following procedure: i) collection of 14 ml of blood in pre-warmed tubes at the hospital's biochemistry laboratory, ii) clotting at 37degreesC for 3 hours, iii) centrifugation at 37degreesC (3,000 RPM for 10 minutes), iiii) freezing of the pellet at 4degreesC for 10 days, to allow generation of cryoprecipitates. Purification, characterization and quantification of cryoglobulins were performed by the same operator (MO), as previously described [22]. Cryoglobulins were classified as type I for monoclonal component, type II for one monoclonal component associated with polyclonal immunoglobulins, type II-III for more than one monoclonal component associated with polyclonal immunoglobulins, and type III for polyclonal immunoglobulins [23],[24]. Type III cryoglobulinemia was considered positive when level was higher than 5 mg/L [22], whereas type II and type II-III cryoglobulins were considered positive regardless of concentration level [22]. CHIKV RNA in cryoprecipitates was searched using RT-PCR, as described elsewhere [21].
###end p 20
###begin p 21
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 518 535 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 537 540 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 713 721 <span type="species:ncbi:9606">patients</span>
Patients also underwent immunological tests: (i) determination of C3 and C4 complement components using an immunonephelemetric method (Dade Behring Paris France), (ii) determination of total haemolytic complement using the total haemolytic complement kit (The Binding Site Saint Egreve France), (ii) search for rheumatoid factors, by latex immunoagglutination (Biomerieux Marcy l'Etoile France), (iv) detection of antinuclear antibodies by indirect immunofluorescence (Eurobio Paris France). Serological screening for hepatitis C virus (HCV) infection was systematically performed using sandwich enzyme-linked immunosorbent assays (Biorad Marne La Coquette France). After 6 months, blood testing for asymptomatic patients was restricted to CHIKV serology and detection of cryoglobulinemia.
###end p 21
###begin title 22
Statistical Analysis
###end title 22
###begin p 23
Chi 2, Kruskall-Wallis and exact Fisher's, two-tailed probability tests were used with a significant p value of 0.05 (Stata 9.0 Software, StataCorp College Station, Texas, USA).
###end p 23
###begin title 24
Results
###end title 24
###begin title 25
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and First Screening for CHIKV Infection
###end title 25
###begin p 26
###xml 163 174 163 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(see below)</italic>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
During the 25 month-study, 66 French patients with clinical suspicion of CHIKV infection were prospectively included. Among them, 51 presented with anti-CHIKV IgM (see below). Fifteen patients remained seronegative for both anti-CHIKV IgM and IgG. No patients had detectable CHIK virus in sera (RT PCR and CHIK V isolation on Vero cell were negative).
###end p 26
###begin p 27
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
###xml 441 448 <span type="species:ncbi:9606">patient</span>
###xml 502 510 <span type="species:ncbi:9606">patients</span>
Sex ratio (M/F) and median age in seropositive patients were respectively 1.04 and 54 years (range: 21 y-78 y), versus 0.67 and 47 years (21 y-75 y) in seronegative patients (no statistical difference). Six CHIKV-infected patients were lost to follow-up after the first consultation. The 45 other patients have been followed in our medical unit for a median duration of 14 months (range: 54 days-25 months), through 2 to 6 consultations per patient; resulting in a total of 138 consultations for CHIKV patients performed up to May 2007.
###end p 27
###begin p 28
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pntd-0000374-t001">Table 1</xref>
###xml 316 320 316 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 465 472 465 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 764 772 <span type="species:ncbi:9606">patients</span>
###xml 933 938 <span type="species:ncbi:9606">women</span>
Table 1 summarizes the demographic, epidemiological and clinical events of the 51 confirmed cases. Ninety-eight percent of the seropositive cases suffered at least once with arthralgia, 71% with tenosynovitis and 20% with transitory PVD. Thirteen patients experienced at least one clinical relapse during follow-up, i.e. became symptomatic again after at least one symptom free month, mostly with subacute arthralgias in hands and feet. Thirteen patients developed de novo transitory PVD, mainly in fingers and sometimes in toes, within the second and third months after the disease onset. No other aetiology (drug, auto-immune disorder, Buerger disease, local trauma) than CHIKV was identified for relapses or PVD. No morphological changes were observed in the 3 patients for whom a digital capillaroscopy was performed. PVD was not significantly associated with gender. Conversely, tenosynovitis was significantly more frequent in women, both on the day of consultation (p = 0.01) or during the previous month (p = 0.04).
###end p 28
###begin title 29
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Characteristics of 51 patients with Chikungunya infection imported from Indian Ocean Islands between April 2005 and October 2006, to Laveran Military hospital, Marseille, France.
###end title 29
###begin p 30
This table reports the most frequent signs and symptoms, regardless of duration.
###end p 30
###begin p 31
###xml 79 82 79 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Simon1">[1]</xref>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of 39 of these patients have been described elsewhere [1].
###end p 31
###begin title 32
Cryglobulinemia Testing
###end title 32
###begin p 33
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 391 399 <span type="species:ncbi:9606">patients</span>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
###xml 500 508 <span type="species:ncbi:9606">patients</span>
###xml 673 680 <span type="species:ncbi:9606">patient</span>
###xml 830 837 <span type="species:ncbi:9606">patient</span>
Among the 51 CHIKV-infected patients, cryoglobulinemia was screened for 48, i.e. 42 patients on first consultation and 6 later during follow-up. Cryoglobulinemia screening was repeated 2 to 5 times for 38 patients during the study period. The median delay between CHIKV acute symptomatology onset and first cryoglobulinemia testing was 45 days (range: 5-640 d). On first consultation, 37/42 patients (88%) were cryoglobulinemic. Among the five patients without cryoglobulinemia: i) three symptomatic patients respectively free of cryoglobulinemia on days 5, 16 and 36 after disease onset, developed cryoglobulinemia on days 27, 45 and 69, respectively; ii) one symptomatic patient free of cryoglobulinemia on his first test at day 124 (a week after a short-term corticotherapy) became positive with a type II on day 204; iii) one patient had been symptom-free for weeks and was not cryoglobulinemic when tested on day 107 after disease onset.
###end p 33
###begin p 34
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
Among the 6 patients first tested at the second consultation, 4 were cryoglobulinemic and two remained negative for cryoglobulin on day 143 and day 355, respectively, while they were both symptom-free. Finally, 94% of the 48 CHIKV-infected tested patients were positive for cryoglobulinemia at least once during their follow-up.
###end p 34
###begin p 35
During the study period, 118 cryoglobulin assays were performed, 83 were positive. There were 61% (51/83) type II, 30% (25/83) type II-III and 8% (7/83) type III. Monoclonal IgM-kappa and IgM-lambda components were found in 56/83 cryoglobulins (68%) and 48/83 (58%), respectively; polyclonal IgM components in 83/83 cryoglobulins (100%). Monoclonal IgA was found in only 2/83 cryoglobulins. Thus, all cryoglobulins associated with CHIKV infection were mixed cryoglobulins.
###end p 35
###begin p 36
###xml 120 122 120 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
The cryoglobulin concentration could be determined for 79/83 cryoglobulinemias. The median cryoglobulin level was 8 mg.L-1 (range: 3-165). No CHIKV was detected by RT-PCR in 24 tested cryoprecipitates.
###end p 36
###begin title 37
Cryoglobulinemia and serological assay for CHIKV infection
###end title 37
###begin p 38
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
###xml 638 646 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
###xml 867 875 <span type="species:ncbi:9606">patients</span>
###xml 954 961 <span type="species:ncbi:9606">patient</span>
When performed on sera kept at 4degreesC before analysis, detection of anti-CHIKV IgM was positive for 45 /66 patients. Among them, cryoglobulinemia was found in 40 patients (89%). Moreover, cryoglobulins were detected in 11 (52%) of the 21 initially seronegative patients. For these 11 patients new ELISA were conducted on sera kept at 37degreesC until analysis, to allow dissolution of putative cryoprecipitates. Anti-CHIKV IgM were found in 6 of these patients and anti CHIKV IgG in 4. Pre-warmed sera were characterized by high levels of specific antibodies and presence of cryoglobulin in 5 /6 cases. When summarizing, a total of 51 patients were serologically confirmed with CHIKV infection. Ninety-four percent where cryoglobulinemic at least once during follow up, while only 27% (4/15) of CHIKV-seronegative patients were cryoglobulinemic (p<0.0001). All 51 patients but one (98%) were positive for anti-CHIKV IgM and 88% for IgG. The remaining patient, unless presenting with typical CHIKV-clinical symptoms, became anti-CHIKV IgG positive only when tested 124 days after disease onset.
###end p 38
###begin title 39
CHIKV-associated cryoglobulinemia, clinical features and corticotherapy
###end title 39
###begin p 40
###xml 595 597 595 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 682 690 682 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus 2</italic>
###xml 729 730 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 898 900 898 900 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 922 924 922 924 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 992 993 992 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</italic>
###xml 993 1001 993 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pntd-0000374-g001">Figure 1</xref>
###xml 1001 1002 1001 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</italic>
###xml 1180 1182 1180 1182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1295 1297 1295 1297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
###xml 707 715 <span type="species:ncbi:9606">patients</span>
###xml 875 880 <span type="species:ncbi:9606">woman</span>
###xml 1023 1028 <span type="species:ncbi:9606">woman</span>
###xml 1243 1251 <span type="species:ncbi:9606">patients</span>
There was a negative correlation between age and cryoglobulin levels (p = 0.012). As arthralgias and cryoglobulinemia were quasi constant (prevalence 98% and 94%, respectively) no statistical association could be tested. No significant difference was found in cryoglobulin type or concentration according to presence of tenosynovitis or number of joints involved (less or more than 10). Although patients with PVD presented with more type II-III cryoglobulins (25%) than patients without PVD (13%), the difference was not significant. Nevertheless a cryoglobulin concentration higher than 8 mg.L-1 (median concentration) was present in 7/31 samples from patients suffering with PVD versus 2/39 samples from patients without PVD (p = 0.06). Two specific clinical cases are particularly illustrative for pathophysiology: (i) the type II-III cryoglobulin level of a 36-year-old woman rose from 32 mg.L-1 on day 40 to 104 mg.L-1 on day 60, while she was just developing a severe Raynaud syndrome (Figure 1); (ii) a 20-year-old woman, whose severe acute stage was marked by transitory myocarditis and finger coldness, also presented high levels of type III cryoglobulin, up to 165 mg.L-1 on day 85. No other specific clinical sign was presented by patients whose cryoglobulin level was below 100 mg.L-1.
###end p 40
###begin title 41
###xml 103 108 <span type="species:ncbi:9606">woman</span>
Left side: Red stage of Raynaud syndrome and swelling of finger joints in a 36-year-old CHIKV-infected woman 6 weeks after disease onset; right side: concomitant cryoprecipitate in her blood.
###end title 41
###begin p 42
###xml 11 19 <span type="species:ncbi:9606">patients</span>
Twenty-six patients received short-term general corticotherapy, mainly prescribed for disabling distal polyarthritis, multiple tenosynovitis or severe PVD, when non-steroidal anti-inflammatory drugs (NSAIDs) were contraindicated (4 cases) or ineffective (22 cases). All of them experienced definitive or transitory improvement of tendon pains, PVD and sometimes arthralgias after this treatment.
###end p 42
###begin p 43
###xml 290 292 290 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 434 436 434 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rd</sup>
###xml 603 605 603 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 109 114 <span type="species:ncbi:9606">woman</span>
The parallel evolution of symptoms and cryoglobulinemia under corticotherapy in a 54-year-old CHIKV-infected woman was particularly illustrative. On day 34 after disease onset, she was disabled by severe polyarthritis and tenosynovitis and a type II cryoglobulin was identified at 15.2 mg.L-1. As NSAIDs were contraindicated because of oral anticoagulation, she received general corticotherapy with progressive withdrawal within the 3rd month. At the end of this treatment, her clinical status improved dramatically while cryoglobulinemia disappeared. After 8 months of evolution, a low level (4.06 mg.L-1) of type II-III cryoglobulin was detected, while she only complained of mild stiffness in the fingers. This case was suggestive for an unexpected role of MC in pathophysiology of late CHIKV manifestations.
###end p 43
###begin title 44
Evolution Of CHIKV-associated cryoglobulinemia
###end title 44
###begin p 45
###xml 365 372 365 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</italic>
###xml 365 372 365 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pntd-0000374-t002"><italic>Table 2</italic></xref>
###xml 592 598 592 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 726 734 726 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pntd-0000374-g002">Figure 2</xref>
###xml 851 858 851 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">table 2</italic>
###xml 851 858 851 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pntd-0000374-t002"><italic>table 2</italic></xref>
###xml 908 910 908 910 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
###xml 938 943 <span type="species:ncbi:9606">woman</span>
###xml 1077 1084 <span type="species:ncbi:9606">patient</span>
Cryoglobulin was screened in 39 patients throughout the follow-up period. The earliest cryoglobulins were detected on day 6 after disease onset. Cryoglobulin prevalence rate was negatively associated with elapsed time after disease onset (p = 0.002). Prevalence remained stable around 80% within the first three months, and decreased to 57% in the second semester (Table 2). Cryoglobulins were still detected in 55% of the 18 patients evaluating for more than a year. Types II and III cryoglobulins seemed to be detected earlier than type II-III cryoglobulins (median delay: 36.5 and 41 days versus 58.5 days, respectively; p = 0.07). The evolution of cryoglobulin levels over time after CHIKV infection onset is presented in Figure 2. Type II and II-III cryoglobulin levels significantly changed over time (type II, p = 0.008; type II-III, p = 0.04; table 2). Interestingly, a type II cryoglobulin at 6 mg.L-1 was detected in a Comorian woman who was still painful one year after her infection in the Comoros archipelago. On day 596, no cryoglobulin was detected, whereas the patient had become asymptomatic for 4 months.
###end p 45
###begin title 46
Evolution of all types cryoglobulin levels over time in 51 Chikungunya-infected travelers, Laveran Military Hospital, Marseille, France.
###end title 46
###begin p 47
The sample results are presented as follows: box represents the interquartile range, the included line figuring the median; lines out of the box represent range with extreme outliers figured as points.
###end p 47
###begin title 48
Cryoglobulin types and levels regarding delay after Chikungunya infection onset, at Laveran Military hospital, Marseille, France.
###end title 48
###begin p 49
p = 0.008.
###end p 49
###begin p 50
p = 0.04.
###end p 50
###begin p 51
p = 0.002 (Kruskall-Wallis test for distribution between the different delays).
###end p 51
###begin p 52
###xml 0 7 0 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pntd-0000374-t003">Table 3</xref>
###xml 126 135 126 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pntd-0000374-g003">Figures 3</xref>
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pntd-0000374-g004">4</xref>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pntd-0000374-g005">5</xref>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pntd-0000374-g006">6</xref>
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pntd-0000374-g007">7</xref>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
Table 3 summarizes the main clinical and biological data of the CHIKV-infected patients at successive times during follow-up. Figures 3, 4, 5, 6 and 7 illustrate examples of clinical and biological evolution after CHIKV infection.
###end p 52
###begin title 53
###xml 45 52 <span type="species:ncbi:9606">patient</span>
Individual follow up of a 62-year-old female patient with CHIKV infection.
###end title 53
###begin p 54
X-axis, month of follow-up; Y-axis, Cryoglobulin level in mg.L-1.
###end p 54
###begin title 55
###xml 45 52 <span type="species:ncbi:9606">patient</span>
Individual follow up of a 41-year-old female patient with CHIKV infection.
###end title 55
###begin p 56
X-axis, month of follow-up; Y-axis, Cryoglobulin level in mg.L-1.
###end p 56
###begin title 57
###xml 45 52 <span type="species:ncbi:9606">patient</span>
Individual follow up of a 36-year-old female patient with CHIKV infection.
###end title 57
###begin p 58
X-axis, month of follow-up; Y-axis, Cryoglobulin level in mg.L-1.
###end p 58
###begin title 59
###xml 43 50 <span type="species:ncbi:9606">patient</span>
Individual follow up of a 62-year-old male patient with CHIKV infection.
###end title 59
###begin p 60
X-axis, month of follow-up; Y-axis, Cryoglobulin level in mg.L-1.
###end p 60
###begin title 61
###xml 45 52 <span type="species:ncbi:9606">patient</span>
Individual follow up of a 66-year-old female patient with CHIKV infection.
###end title 61
###begin p 62
X-axis, month of follow-up; Y-axis, Cryoglobulin level in mg.L-1.
###end p 62
###begin title 63
###xml 37 45 <span type="species:ncbi:9606">patients</span>
Clinical and biological status of 51 patients with Chikungunya infection at successive follow-up delays, Laveran Military hospital, Marseille, France (M: month).
###end title 63
###begin p 64
###xml 4 11 <span type="species:ncbi:9606">patient</span>
one patient underwent two cryoglobulin tests, the one performed one week after general corticotherapy is not presented here.
###end p 64
###begin p 65
###xml 10 18 <span type="species:ncbi:9606">patients</span>
these two patients remained symptomatic even after 15 months.
###end p 65
###begin title 66
Other Laboratory Testing
###end title 66
###begin p 67
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 194 197 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Neither antinuclear antibody nor rheumatoid factors were found during follow-up. C3, C4 complement fractions and haemolytic complement levels remained normal. All patients were seronegative for HCV.
###end p 67
###begin title 68
Discussion
###end title 68
###begin p 69
###xml 193 201 <span type="species:ncbi:9606">patients</span>
Our study was an empiric prospective study of symptomatic CHIKV-infected travelers coming back from Western Indian Ocean. Thus, follow-up for cryoglobulinemia was not performed in seronegative patients in the absence of ethic committee consent.
###end p 69
###begin p 70
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 145 148 145 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Fourie1">[3]</xref>
###xml 250 253 250 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Brighton1">[4]</xref>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
Up to now, pathogenesis of CHIKV-induced rheumatism remains unknown. Fourie et al. identified low titers of rheumatoid factor in CHIKV infection [3], whereas no antinuclear antibodies or rheumatoid factors were detected here like in previous studies [4]. We identified for the first time the association between CHIKV infection and cryoglobulinemia among infected travelers. As no type I cryoglobulin (composed of one monoclonal immunoglobulin) was detected in our patients, CHIKV seems to induce only mixed cryoglobulinemia (MC), either type II, II-III or III.
###end p 70
###begin p 71
###xml 76 80 76 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Tedeschi1">[19]</xref>
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Dispenzieri1">[20]</xref>
###xml 348 352 348 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Tedeschi1">[19]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Dispenzieri1">[20]</xref>
###xml 294 311 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 313 316 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
MC has already been described in miscellaneous acute and chronic infections [19],[20]. In these cryoglobulinemia seemed to rapidly decrease and disappear within a few weeks of pathogen clearance, although persisting MC has been observed in few chronic infections, the most common being chronic hepatitis C virus (HCV) (MC prevalence range: 20-55%) [19],[20]. In our study, the strength of association between CHIKV infection and MC was much higher 94%. A biased high prevalence of CHIKV-MC due to use of a highly sensitive method can be ruled in regard of the frequent negativity of cryoglobulinemia detection over time during follow-up.
###end p 71
###begin p 72
###xml 192 196 192 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Laurent1">[25]</xref>
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Agnello1">[26]</xref>
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Cacoub1">[27]</xref>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Oliver1">[22]</xref>
###xml 456 462 456 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 617 621 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Ozden1">[28]</xref>
###xml 648 654 648 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 819 823 819 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-JaffarBandjee1">[29]</xref>
###xml 183 191 <span type="species:ncbi:9606">patients</span>
###xml 291 294 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 430 433 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 554 561 <span type="species:ncbi:9606">patient</span>
###xml 789 796 <span type="species:ncbi:9606">patient</span>
###xml 1223 1231 <span type="species:ncbi:9606">patients</span>
The persistence of CHIKV-associated MC (CHIKV-MC) was unexpected, as the CHIKV genome has never been detected in blood after 12 days of disease evolution, even in chronic symptomatic patients [25]. Consistently, we failed to detect CHIKV-RNA in the cryoprecipitates, as described in chronic HCV infection [26],[27]. The absence of chronic viremia could also explain the much lower level of CHIKV-MC than those observed in chronic HCV infection [22]. Ozden et al. recently showed the presence of CHIKV in muscle satellite cells of a non-immunocompromised patient who was still painful three months after disease onset [28]. Moreover, Jaffar-Bandjee et al., using molecular tools, evidenced persistence of CHIKV in perivascular macrophages of synovial tissue in a chronic elbow hygroma of a patient infected for one year [29]. This discovery suggests that CHIKV can induce a chronic infection with active replication, conversely to most other arboviruses. Persistence of CHIKV also seemed to stimulate host immunity, as inflammation with macrophages and T cells was locally concomitantly observed. Thus, viral replication could be involved in the prolonged persistence of anti-CHIKV IgM and, as a consequence, of CHIKV-MC in patients with long-persisting symptoms. CHIKV-MC should be the possible "missing link" between CHIKV and some symptoms of the chronic stage.
###end p 72
###begin p 73
###xml 666 670 666 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e.</italic>
###xml 775 779 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Casato1">[30]</xref>
###xml 111 118 <span type="species:ncbi:9606">patient</span>
###xml 761 764 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 806 813 <span type="species:ncbi:9606">patient</span>
###xml 1263 1271 <span type="species:ncbi:9606">patients</span>
###xml 1332 1340 <span type="species:ncbi:9606">patients</span>
The second main finding is the existence of false seronegativity in one out of three and a half CHIKV-infected patient with typical clinical presentation of CHIKV infection when using "classical" ELISA assay at room temperature. This phenomenon can be responsible for non-recognition of CHIKV infection in individuals with chronic rheumatism, leading to useless explorations, as well as underestimation of seroprevalence in an endemic/epidemic area. Considering the high prevalence of CHIKV-MC in our cohort, we assume that cryoglobulinemia may be a significant factor in misdiagnosing the disease when using "conventional" serology. Specific anti-CHIKV antibodies, i.e. IgM and IgG, could all be trapped in the cryoprecipitate, as already described in chronic HCV infection [30]. Therefore, when facing a patient with a clinical suspicion of CHIKV infection and with paradoxical seronegativity, we recommend the following procedure: at least pre-warmed the serum at 37degreesC before serology testing or, preferably, manage the blood sample as required for any cryoglobulin research: sampling and centrifugation at 37degreesC, decantation and serum pre-warming before the ELISA assays. However, considering the high prevalence of MC among our CHIKV-seronegative patients (40%) and the unexpected persistent seronegativity in a few patients with a high clinical suspicion of CHIKV-infection, we cannot exclude some residual false negative results due to the precipitation of CHIKV-MC before blood centrifugation.
###end p 73
###begin p 74
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Tedeschi1">[19]</xref>
###xml 121 125 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Dispenzieri1">[20]</xref>
###xml 611 613 611 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nd</sup>
###xml 622 624 622 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rd</sup>
###xml 660 663 660 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Simon1">[1]</xref>
###xml 159 166 <span type="species:ncbi:9606">patient</span>
###xml 810 813 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 996 1004 <span type="species:ncbi:9606">patients</span>
Chronic MC is commonly associated with various symptoms, mostly arthralgias, purpura, weakness and Raynaud syndrome [19],[20]. In our study, no CHIKV-infected patient presented the complete clinical triad associated with MC, but arthralgias were present in all and combined with PVD in 24%. The concomitancy of arthralgias and cryoglobulinemia in more than 90% of the cases is consistent, although not demonstrative, with an involvement of cryoglobulin in arthralgias. Frequent exacerbation of rheumatic pain and handicap, and the occasional incidence of transitory PVD have been recently described within the 2nd and/or 3rd months after CHIKV-infection onset [1]. These clinical manifestations are synchronous with increasing cryoglobulin levels. The low cryoglobulin blood levels -when compared with chronic HCV infection- could explain the lack of vascular purpura in our cohort. No significant association between PVD and CHIKV-MC prevalence was observed, possibly due to the small number of patients, although there was a positive trend between presence of PVD and CHIKV-MC levels (p = 0.06). We failed to find any significant association between CHIKV-MC type or level and any other sign or symptom.
###end p 74
###begin p 75
###xml 733 737 733 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Sourisseau1">[31]</xref>
###xml 5 13 <span type="species:ncbi:9606">patients</span>
###xml 700 708 <span type="species:ncbi:9606">patients</span>
Most patients self-declared improvements after short-term general corticotherapy. In few of them we could evidence concomitant CHIKV-MC disappearance. Corticosteroids could interfere through two actions: immunosuppression of B lymphocyte activation and/or decrease of joint and tendon inflammation. Randomized studies are needed to confirm the benefits and risks of general corticotherapy and to specify therapeutic modalities in chronic CHIKV-associated rheumatism. Complementary investigations are also required to determine whether antiviral drugs, such as chloroquine or interferon could be helpful in stopping CHIKV replication in muscle satellite cells and MC production in symptomatic chronic patients, as suggested elsewhere [31].
###end p 75
###begin p 76
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Cicardi1">[32]</xref>
###xml 1254 1258 1254 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Tedeschi1">[19]</xref>
###xml 1675 1678 1675 1678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pntd.0000374-Brighton1">[4]</xref>
###xml 284 287 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 720 728 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
###xml 953 961 <span type="species:ncbi:9606">patients</span>
###xml 1186 1189 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1445 1453 <span type="species:ncbi:9606">patients</span>
Finally, the present work also shows the evolution of CHIKV-MC types and levels over time. Schematically, type III or type II cryoglobulin appear first (median delay: around 40 days), followed by type II-III (median delay: around 2 months), conversely to what is usually described in HCV infection [32]. Cryoglobulin levels reached their acme within the 3rd month after disease onset and remained stable up to the 6th, before a slow decline. Regarding the parallel evolution of CHIKV-MC and anti-CHIKV IgM antibodies over time and the systematic detection of IgM in CHIKV-MC, the direct involvement of these antibodies in cryoprecipitates can be suspected. After 6 months of evolution, CHIKV-MC levels decrease for most patients, in parallel with obvious clinical improvement. No cryoglobulin was detected in most of patients after they became symptom-free, whatever the delay of recovery. However the evolution was not linear. About one quarter of the patients underwent clinical relapses with distal arthralgias and a concomitant increase or reappearance of cryoglobulin. The disappearance of CHIKV-MC could be predictive for a clinical cure in chronic CHIKV disease, as described in HCV infection after interferon and ribavirin or rituximab treatment [19]. Further studies with long time follow-up are required to determine if type or level of early CHIKV-MC has a real prognostic value. In Brighton's experience, 87.9% of 107 CHIKV-infected patients self-declared cured 3 years after disease onset, while 12.1% mentioned persistent symptoms including occasional discomfort, persistent joint stiffness, or stiffness and pain and effusion (3.7%, 2.8%, and 6% respectively) [4].
###end p 76
###begin p 77
###xml 128 138 128 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Aedes spp.</italic>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
CHIKV infection is currently spreading in Africa, Indian Ocean, India and Southeastern Asia and threats many others areas where Aedes spp. is present. It is responsible for long-persisting symptoms, which severely impair quality of life of CHIKV-infected patients although natives or travelers. Thus, the identification of very high prevalence of CHIKV-MC is of importance. First, its presence can induce false negativity in serology performed at room temperature; leading to the recommendation of using pre-warmed sera for serology both for individual diagnosis, and seroprevalence estimation in endemic areas. Second, CHIKV-MC may be involved in the pathogenesis of the chronic stage, mainly CHIKV-associated chronic rheumatism and PVD. Third, its prolonged disappearance could be a marker of the definitive clinical cure.
###end p 77
###begin p 78
###xml 215 217 215 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 327 331 327 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#232;mes</sup>
###xml 324 375 324 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XII<sup>&#232;mes</sup> Actualit&#233;s du Pharo et de l'H&#244;pital Laveran</italic>
This work was supported by the French Service de Sante des Armees. We are grateful to Mrs Mathilde Guionnet and Dr Pierre Hance for their technical support. Preliminary results of this study were presented at the 16th European Congress of Clinical Microbiology and Infectious Diseases on April 1-4, Nice, France, and at the XIIemes Actualites du Pharo et de l'Hopital Laveran, Marseille, France, September 7-9, 2006.
###end p 78
###begin title 79
References
###end title 79
###begin article-title 80
Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases.
###end article-title 80
###begin article-title 81
The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic.
###end article-title 81
###begin article-title 82
Rheumatoid arthritic syndrome after chikungunya fever.
###end article-title 82
###begin article-title 83
###xml 0 17 <span type="species:ncbi:37124">Chikungunya virus</span>
Chikungunya virus infection. A retrospective study of 107 cases.
###end article-title 83
###begin article-title 84
Emerging viral diseases of Southeast Asia and the Western Pacific.
###end article-title 84
###begin article-title 85
###xml 23 40 <span type="species:ncbi:37124">Chikungunya virus</span>
Epidemic resurgence of Chikungunya virus in democratic Republic of the Congo: identification of a new central African strain.
###end article-title 85
###begin article-title 86
Chikungunya outbreaks-the globalization of vectorborne diseases.
###end article-title 86
###begin article-title 87
Chikungunya disease outbreak, Reunion Island.
###end article-title 87
###begin article-title 88
Chikungunya epidemic in India: a major public-health disaster.
###end article-title 88
###begin article-title 89
Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic.
###end article-title 89
###begin article-title 90
Outbreak news. Chikungunya and dengue, south-west Indian Ocean.
###end article-title 90
###begin article-title 91
Cases of chikungunya fever imported from the islands of the South West Indian Ocean to Paris, France.
###end article-title 91
###begin article-title 92
Chikungunya fever diagnosed among international travelers-United States, 2005-2006.
###end article-title 92
###begin article-title 93
Update: chikungunya fever diagnosed among international travelers-United States, 2006.
###end article-title 93
###begin article-title 94
###xml 6 23 <span type="species:ncbi:37124">chikungunya virus</span>
Novel chikungunya virus variant in travelers returning from Indian Ocean islands.
###end article-title 94
###begin article-title 95
Chikungunya fever is transmitted locally in Europe for first time.
###end article-title 95
###begin article-title 96
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients.
###end article-title 96
###begin article-title 97
Chikungunya-induced myopericarditis toward an increase of dilated cardiomyopathy in epidemic countries?
###end article-title 97
###begin article-title 98
Cryoglobulinemia.
###end article-title 98
###begin article-title 99
Cryoglobulinemia.
###end article-title 99
###begin article-title 100
Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African Chikungunya viruses.
###end article-title 100
###begin article-title 101
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 118 129 <span type="species:ncbi:11103">hepatitis C</span>
[Cryoglobulins: detection, type determination and quantitation. A study of healthy subjects and patients with chronic hepatitis C].
###end article-title 101
###begin article-title 102
Characterization of cryoglobulins by immunoblotting.
###end article-title 102
###begin article-title 103
Biologic and clinical significance of cryoglobulins. A report of 86 cases.
###end article-title 103
###begin article-title 104
###xml 117 134 <span type="species:ncbi:37124">chikungunya virus</span>
Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus.
###end article-title 104
###begin article-title 105
###xml 11 28 <span type="species:ncbi:11103">hepatitis C virus</span>
A role for hepatitis C virus infection in type II cryoglobulinemia.
###end article-title 105
###begin article-title 106
###xml 27 44 <span type="species:ncbi:11103">hepatitis C virus</span>
Mixed cryoglobulinemia and hepatitis C virus.
###end article-title 106
###begin article-title 107
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 43 60 <span type="species:ncbi:37124">chikungunya virus</span>
Human muscle satellite cells as targets of chikungunya virus infection.
###end article-title 107
###begin article-title 108
Identification des cellules cibles et des mecanismes physiopathologiques du virus Chikungunya. chikungunya et autres arboviroses emergentes en milieu tropical.
###end article-title 108
###begin article-title 109
###xml 7 24 <span type="species:ncbi:11103">hepatitis C virus</span>
Occult hepatitis C virus infection in type II mixed cryoglobulinaemia.
###end article-title 109
###begin article-title 110
Characterization of Reemerging Chikungunya Virus.
###end article-title 110
###begin article-title 111
###xml 71 79 <span type="species:ncbi:9606">patients</span>
###xml 93 104 <span type="species:ncbi:11103">hepatitis C</span>
Prevalence and risk factors for the presence of serum cryoglobulins in patients with chronic hepatitis C.
###end article-title 111
###begin p 112
The authors have declared that no competing interests exist.
###end p 112
###begin p 113
This work was supported by the French Service de Sante des Armees. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 113

